Market: NMS |
Currency: USD
Address: 245 Main Street
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
📈 Immuneering Corporation Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$16.83
-
Upside/Downside from Analyst Target:
214.05%
-
Broker Call:
12
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
0-10%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2026-03-20
-
EPS Estimate:
-0.31
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Immuneering Corporation
| Date | Reported EPS |
|---|
| 2026-03-19 (estimated upcoming) | - |
| 2025-11-12 | -0.38 |
| 2025-08-13 | -0.4 |
| 2025-05-05 | -0.42 |
| 2025-03-20 | -0.58 |
| 2024-11-13 | -0.49 |
| 2024-08-06 | -0.47 |
| 2024-05-07 | -0.49 |
| 2024-03-01 | -0.52 |
| 2023-11-09 | -0.43 |
| 2023-08-03 | -0.43 |
| 2023-05-04 | -0.51 |
| 2023-03-06 | -0.5 |
| 2022-11-10 | -0.49 |
| 2022-08-10 | -0.44 |
| 2022-05-10 | -0.49 |
| 2022-03-10 | -0.05 |
| 2021-11-09 | -0.47 |
| 2021-09-09 | -1.61 |
📰 Related News & Research
No related articles found for "immuneering corporation".
